Quarterly report pursuant to Section 13 or 15(d)

3. ACQUISITION OF AVENTINE (Details - Pro forma)

v3.3.0.814
3. ACQUISITION OF AVENTINE (Details - Pro forma) - Aventine - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2015
Sep. 30, 2014
Sep. 30, 2015
Sep. 30, 2014
Net sales - pro forma $ 380,622 $ 429,373 $ 1,107,919 $ 1,267,853
Cost of goods sold - pro forma 379,302 400,260 1,102,278 1,137,410
Selling, general and administrative expenses - pro forma 7,346 8,892 29,144 24,568
Net income (loss) - pro forma $ (6,182) $ (117) $ (34,226) $ 4,400
Diluted net income (loss) per share - pro forma $ (.15) $ 0.00 $ (.71) $ .11
Diluted weighted-average shares - pro forma 41,861,000 42,062,000 47,945,000 39,828,000